Overview

TD-6450 MAD Study in HCV Infected Subjects

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

This proof of concept study is designed to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of TD-6450 in treatment naïve subjects with GT-1, GT-2 or GT-3 chronic HCV.

Phase:

Phase 1

Details

Lead Sponsor:

Theravance Biopharma
Theravance Biopharma R & D, Inc.